What Happened
- Pharmaceutical giant Novartis reached a confidential settlement with the estate of Henrietta Lacks, resolving a lawsuit alleging that Novartis unjustly profited from HeLa cells — cervical cancer cells taken from Lacks without her knowledge or consent in 1951 and commercialised for decades.
- The settlement was finalised in federal court in Maryland; financial terms were not disclosed.
- Lacks' estate alleged Novartis used HeLa cells in developing multiple commercial products, including the herpes drug Famvir, the CAR-T cancer therapy Kymriah, and the gene therapy Zolgensma — cumulatively generating billions of dollars in revenue.
- This is the second such settlement: in 2023, Lacks' estate reached a settlement with biotechnology company Thermo Fisher Scientific. Active litigation against Ultragenyx and Viatris (pharmaceutical companies) continues.
- The case has reignited global debate on informed consent in medical research, the commercialisation of biological materials, and racial justice in the history of biomedical science.
Static Topic Bridges
Informed Consent and the Ethics of Human Biological Research
Informed consent is a foundational principle of medical and research ethics, requiring that a patient or research subject voluntarily agrees to a procedure or use of their biological materials after being fully informed of the nature, risks, benefits, and alternatives. The principle derives from the Nuremberg Code (1947), established after Nazi medical experiments during World War II, and was codified globally through the Declaration of Helsinki (1964, with multiple revisions). The Belmont Report (1979), produced by the US National Commission for the Protection of Human Subjects, articulated three core principles: Respect for Persons (autonomy, informed consent), Beneficence (maximise benefits, minimise harm), and Justice (equitable distribution of research burdens and benefits). In India, the ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017) governs research ethics, requiring free, prior, and informed consent.
- Nuremberg Code (1947): first international standards on voluntary consent in research
- Declaration of Helsinki (1964): World Medical Association; covers research on human subjects; revised multiple times (latest: 2013)
- Belmont Report (1979): three principles — Respect for Persons, Beneficence, Justice; basis for US federal research regulations (45 CFR 46, "Common Rule")
- ICMR National Ethical Guidelines (2017): India's framework for biomedical research ethics
- Henrietta Lacks case: cells taken 1951 at Johns Hopkins Hospital without consent or compensation; she died in 1951 at age 31
Connection to this news: Lacks' cells were taken in an era when patients had no legal right to consent to the use of their biological materials — the Novartis settlement represents retroactive legal accountability for a system that the Belmont Report and subsequent frameworks were designed to prevent.
HeLa Cells: Scientific Significance and Biopiracy Parallels
HeLa cells, derived from Henrietta Lacks' cervical cancer tumour, became the first human cell line to grow and reproduce continuously in a laboratory — a breakthrough that had eluded scientists for decades. Since 1951, HeLa cells have been used in over 110,000 scientific studies, contributing to: development of the polio vaccine (Jonas Salk, 1952-53), understanding of cancer biology and cell division, development of in vitro fertilisation (IVF) techniques, genetic mapping of the human genome, COVID-19 vaccine development, and testing of drugs including Kymriah (Novartis' CAR-T therapy) and Zolgensma (gene therapy). The concept of biopiracy — the exploitation of biological resources or traditional knowledge without equitable sharing of benefits — finds a parallel in the HeLa case: a Black woman's cells were commercialised without consent, compensation, or acknowledgement, in a racially stratified healthcare system.
- HeLa cells: taken from Henrietta Lacks' cervical tumour on 8 February 1951 at Johns Hopkins Hospital, Baltimore
- First continuously reproducing human cell line: enabled modern cell biology
- Lacks died: 4 October 1951 (at age 31); cells continued to be cultured and shared globally
- Novartis products developed using HeLa cells: Famvir (herpes), Kymriah (CAR-T, leukemia), Zolgensma (gene therapy for spinal muscular atrophy — world's most expensive drug at ~$2.1 million)
- Biopiracy framework: Convention on Biological Diversity (CBD, 1992) + Nagoya Protocol (2010) govern access and benefit sharing for biological resources — mainly for genetic resources of states, but ethically applicable to human biological materials
Connection to this news: The Novartis settlement acknowledges that the commercialisation of Lacks' cells without consent or compensation was a violation of both bioethical norms and racial justice — directly connecting science, law, and equity in a way UPSC Mains GS3 and GS2 questions regularly probe.
Racial Justice, Historical Exploitation, and Reparative Ethics
Henrietta Lacks was a Black woman in 1950s America, where racial segregation defined healthcare access and research ethics were non-existent for Black patients. Johns Hopkins Hospital (where her cells were taken) served Black patients in a segregated ward. The Tuskegee Syphilis Study (1932-72) — in which Black men with syphilis were left untreated without their knowledge to study disease progression — is the most notorious parallel case of racially-motivated medical exploitation. These cases collectively shaped the US regulatory response (National Research Act 1974, Belmont Report 1979, Common Rule) and inform contemporary debates on health equity, representation in clinical trials, and the ethics of biobanking. In India, the Protection of Plant Varieties and Farmers' Rights Act, 2001 (PPV&FR Act) and the Biological Diversity Act, 2002 provide frameworks for benefit-sharing from biological resources — a statutory response to concerns about exploitation of traditional knowledge and genetic resources.
- Tuskegee Syphilis Study: 1932-72; US Public Health Service; studied untreated syphilis in 399 Black men without consent; ended after public exposure
- National Research Act, 1974 (US): enacted in response to Tuskegee; created National Commission → Belmont Report
- India's Biological Diversity Act, 2002: regulates access to biological resources and benefit sharing; National Biodiversity Authority (NBA) established
- PPV&FR Act, 2001: protects farmers' rights to seeds and breeders' rights; benefit-sharing for use of farmers' varieties
- Nagoya Protocol (2010): supplementary to CBD; access and benefit sharing framework for genetic resources
Connection to this news: The Lacks case illustrates how historical exploitation of marginalised communities' biological materials persists as a systemic issue — the Novartis settlement is simultaneously a legal, bioethical, and racial justice development.
Key Facts & Data
- Henrietta Lacks: born 1 August 1920; died 4 October 1951 (age 31); Baltimore, Maryland
- HeLa cells taken: 8 February 1951 at Johns Hopkins Hospital without consent
- HeLa cells used in: 110,000+ scientific studies; polio vaccine (1952-53), COVID-19 vaccines, Kymriah, Zolgensma
- Zolgensma: world's most expensive drug (~$2.1 million per dose); gene therapy for spinal muscular atrophy
- Novartis settlement: confidential; second settlement by Lacks estate (first with Thermo Fisher, 2023)
- Active litigation: against Ultragenyx and Viatris
- Belmont Report: 1979; three principles: Respect for Persons, Beneficence, Justice
- Nuremberg Code: 1947; Declaration of Helsinki: 1964 (revised 2013)
- ICMR National Ethical Guidelines: 2017
- Tuskegee Syphilis Study: 1932-72; led to National Research Act 1974
- India's Biological Diversity Act: 2002; Nagoya Protocol: 2010